Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States

Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, and Glooko, Inc., a global leader in chronic condition management, today announced a partnership to integrate Better Therapeutics’ AspyreRx digital behavioral treatment for type 2 diabetes (T2D) into Glooko’s diabetes management platform. This collaboration will enable healthcare providers in the United States who use the Glooko platform to identify suitable patients for AspyreRx, facilitate prescriptions, and track patients throughout their treatment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240103238870/en/

In the United States alone, Glooko’s solutions have aided over 3.4 million people with diabetes and are utilized in nearly 5,000 clinic locations. AspyreRx will be accessible on the Glooko healthcare provider (HCP) platform in the U.S. as a new treatment option. Additionally, by leveraging Glooko’s 'precision engagement' functionality, patients who are suitable candidates for AspyreRx will be flagged for healthcare providers.

“We are very pleased to partner with Better Therapeutics to add AspyreRx to the Glooko platform,” stated Russ Johannesson, CEO of Glooko. “This partnership will facilitate access to an important new treatment option for healthcare providers in the Glooko network, enabling them to better manage their patient populations and enhance health outcomes for patients with T2D.”

Frank Karbe, CEO of Better Therapeutics, said, “Glooko is an ideal partner for us to support the adoption of AspyreRx, given the extensive overlap between providers using the Glooko platform and those we have identified as early adopters for AspyreRx. Glooko’s precision engagement has the potential to accelerate access to AspyreRx for patients who may benefit from this innovative new treatment.”

About Glooko

Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care platforms. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko is globally deployed in over 30 countries and 8,000+ clinical locations.